Skip to main content
Clinical Trials/NCT00196378
NCT00196378
Completed
Phase 3

A Randomized, Multicenter, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Synthetic Conjugated Estrogens, B (Enjuvia) 0.3 mg Tablets for the Treatment of Vulvovaginal Atrophy in Healthy Postmenopausal Women

Duramed Research1 site in 1 country300 target enrollmentNovember 2004

Overview

Phase
Phase 3
Intervention
Synthetic Conjugated estrogens, B
Conditions
Menopause
Sponsor
Duramed Research
Enrollment
300
Locations
1
Primary Endpoint
Mean change in maturation index
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

This is a two-arm, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy of Enjuvia 0.3 mg tablets for the treatment of moderate to severe symptoms of vulvovaginal atrophy in postmenopausal women with or without a hysterectomy and/or oophorectomy.

Detailed Description

The study will include a screening period up to 4 weeks and a 12-week treatment period. The overall study duration for participants will be approximately 16 weeks. Study participants will undergo physical and gynecological exams, and blood tests for clinical laboratory assessments. All patients with a uterus will undergo transvaginal ultrasound.

Registry
clinicaltrials.gov
Start Date
November 2004
End Date
February 2006
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Naturally or surgically postmenopausal
  • Moderate or severe symptoms of vaginal atrophy (ie, dryness, itching, pain, uncomfortable intercourse)

Exclusion Criteria

  • Known sensitivity or contraindication to estrogens or progestins
  • History or current diagnosis of endometrial hyperplasia
  • Recent history of vaginal bleeding of unknown cause
  • Recent history or diagnosis of endometriosis
  • Any contraindication to estrogen therapy

Arms & Interventions

1

Intervention: Synthetic Conjugated estrogens, B

2

Intervention: Placebo

Outcomes

Primary Outcomes

Mean change in maturation index

Time Frame: Randomization to Week 12

Mean change in the symptom identified by the patient to be most bothersome

Time Frame: Randomization to Week 12

Mean change in vaginal pH

Time Frame: Randomization to Week 12

Secondary Outcomes

  • Safety and tolerability of Enjuvia(Duration of study)

Study Sites (1)

Loading locations...

Similar Trials